

## Pre - PA Allowance

None

---

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have the following:

1. Advanced or metastatic breast cancer

**AND ONE** of the following:

- a. Patient has a *PIK3CA*-mutation as detected by an FDA approved test
  - i. Breast cancer is endocrine-resistant
  - ii. Used in combination with inavolisib and fulvestrant
  - iii. Patient has experienced recurrence on or after completing adjuvant endocrine therapy
- b. Patient is **NOT** *PIK3CA*-mutated
  - i. Used in combination with an aromatase inhibitor or fulvestrant

**AND ALL** of the following:

- a. Hormone receptor (HR)-positive
- b. Human epidermal growth factor receptor 2 (HER2)-negative
- c. Males must have concomitant suppression of testicular steroidogenesis

---

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

1. Well-Differentiated/Dedifferentiated Liposarcoma (WD-DDLS)

## Prior - Approval Limits

**Duration** 12 months

---

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

**Diagnoses**

Patient must have the following:

1. Advanced or metastatic breast cancer

**AND ONE** of the following:

- a. Patient has a *PIK3CA*-mutation
  - i. Used in combination with inavolisib and fulvestrant
- b. Patient is **NOT** *PIK3CA*-mutated
  - i. Used in combination with an aromatase inhibitor or fulvestrant

**AND ALL** of the following:

- a. Males must have concomitant suppression of testicular steroidogenesis
  - b. **NO** disease progression or unacceptable toxicity
- 

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

1. Well-Differentiated/Dedifferentiated Liposarcoma (WD-DDLS)

**AND** the following:

- a. **NO** disease progression or unacceptable toxicity

**Prior - Approval *Renewal* Limits**

Same as above